Ads
related to: Copd Treatments
Search results
ResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expectations with Strong Growth
GuruFocus.com via Yahoo Finance· 4 days agoCompany Overview ResMed, a global leader in respiratory care devices, continues to innovate in the ...
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation...
Benzinga· 12 hours ago"Oral clofazimine has been utilized as a treatment option for patients living with NTM lung disease and we believe that by reducing the dose and administering it directly ...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Morningstar· 5 days agoSanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 ...
20 Fastest Growing Health Tech Companies in the World
Insider Monkey via Yahoo Finance· 4 days agoIn this article, we will be taking a look at the 20 fastest growing health tech companies in the...
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American...
WTNH-TV New Haven· 14 hours agoForesee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate...
Sanofi to report earnings first-quarter earnings Thursday
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoSanofi, a drug company that has operations in Monroe County, will report first-quarter 2024 results...
ResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expe
Guru Focus· 4 days agoResMed, a global leader in respiratory care devices, continues to innovate in the treatment of sleep apnea, COPD, and other chronic diseases. With a significant ...
Teacher says pleas for better ventilation were ignored, then he was diagnosed with lung disease
KSL Salt Lake City· 3 days agoThe following story was reported by the Utah Investigative Journalism Project in partnership with...
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore...
Morningstar· 4 days ago“Bezisterim” has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 11 hours ago“Oral clofazimine has been utilized as a treatment option for patients living with NTM lung disease and we believe that by reducing the dose and administering it directly ...